Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 14/20 | 0.75 |
| ▸ | CSF1R | P07333 | 13/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.75 |
| ▸ | KIT | P10721 | 3/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.75 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1698962 | 0.97 | FLT3 (0.71) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698846 | 0.94 | FLT3 (0.72) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698712 | 0.91 | FLT3 (0.68) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698693 | 0.91 | FLT3 (0.76) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL9980605 | 0.90 | FLT3 (0.64) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698582 | 0.89 | FLT3 (0.72) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698701 | 0.86 | FLT3 (1.00) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL9978910 | 0.85 | CSF1R (0.61) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698832 | 0.85 | CSF1R (0.70) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698903 | 0.84 | FLT3 (0.78) | FLT3CSF1RPDGFRBKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296722-B2 | Azolyl urea compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296722-B2 | Azolyl urea compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2011150198-A1 | AZOLYL UREA COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | CSF1R, CSF3R, ARG1 | FLT3 4/4885CSF1R 1/4885PDGFRB 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.